|
|
Blood, 15 December 2004, Vol. 104, No. 13, pp. 3965-3970.
Prepublished online as a Blood First Edition Paper on August 17, 2004; DOI 10.1182/blood-2004-02-0598.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice
Cristina P. Vicente,
Li He,
Mauro S. G. Pavão, and
Douglas M. Tollefsen
From the Departments of Medicine and Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, MO; and Laboratório de Tecido Conjuntivo, Hospital Universitário and Departamento de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Heparin cofactor II (HCII) is a plasma protein that inhibits thrombin rapidly in the presence of dermatan sulfate or heparin. We previously reported that the time to thrombotic occlusion of the carotid artery after photochemical injury was shorter in HCII-deficient mice than in wild-type control animals. In this paper, we describe the antithrombotic activity of dermatan sulfate in wild-type and HCII-deficient mice. Intravenous administration of porcine skin dermatan sulfate induced a dose-dependent prolongation of the carotid artery occlusion time in HCII+/+ mice that was not observed in HCII-/- animals. Pharmacokinetic studies suggested that porcine skin dermatan sulfate expresses antithrombotic activity after being transferred from the plasma to sites in the vessel wall. Using invertebrate dermatan sulfate preparations, we showed that N-acetylgalactosamine-4-O-sulfate residues are required for the HCII-dependent antithrombotic effect. Furthermore, the invertebrate dermatan sulfates, which have higher charge densities than mammalian dermatan sulfate, slightly prolonged the thrombotic occlusion time of HCII-/- mice. These results indicate that HCII mediates the antithrombotic effect of porcine skin dermatan sulfate after injury to the carotid arterial endothelium in mice, whereas more highly charged dermatan sulfates possess weak antithrombotic activity independent of HCII. (Blood. 2004;104:3965-3970)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. He, T. K. Giri, C. P. Vicente, and D. M. Tollefsen
Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II
Blood,
April 15, 2008;
111(8):
4118 - 4125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. C. Werneck, C. P. Vicente, J. S. Weinberg, A. Shifren, R. A. Pierce, T. J. Broekelmann, D. M. Tollefsen, and R. P. Mecham
Mice lacking the extracellular matrix protein MAGP1 display delayed thrombotic occlusion following vessel injury
Blood,
April 15, 2008;
111(8):
4137 - 4144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Osborne, R. A. Daniel, K. Desilva, and R. B. Seymour
Antithrombin activity and disaccharide composition of dermatan sulfate from different bovine tissues
Glycobiology,
March 1, 2008;
18(3):
225 - 234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Vicente, L. He, and D. M. Tollefsen
Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice
Blood,
December 15, 2007;
110(13):
4261 - 4267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Westrick, M. E. Winn, and D. T. Eitzman
Murine Models of Vascular Thrombosis
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2007;
27(10):
2079 - 2093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Tollefsen
Heparin Cofactor II Modulates the Response to Vascular Injury
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2007;
27(3):
454 - 460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Halldorsdottir, L. Zhang, and D. M. Tollefsen
N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate
Glycobiology,
August 1, 2006;
16(8):
693 - 701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
